BEM 015
Alternative Names: BEM-015Latest Information Update: 01 Sep 2022
At a glance
- Originator Shanghai Benemae Pharmaceutical
- Class Anticoagulants; Monoclonal antibodies
- Mechanism of Action Factor XI inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Thrombosis
Most Recent Events
- 27 Jul 2022 Shanghai Benemae Pharmaceutical intends to file IND application (Shanghai Benemae Pharmaceutical pipeline; July 2022)
- 21 Jul 2022 Early research in Thrombosis in China (Parenteral) (Shanghai Benemae Pharmaceutical pipeline, July 2022)
- 20 Jul 2022 Early research in Thrombosis (Prevention) in China (Parenteral) (Shanghai Benemae Pharmaceuticsl pipeline; July 2022)